[ad_1]
Progression-free survival with the multitarget PAM inhibitor approaches 10 months after anti-CDK4/6 and aromatase inhibitor failure.
Medscape Medical News
[ad_2]
Source link : https://www.medscape.com/viewarticle/gedatolisib-combo-approved-advanced-breast-cancer-2026a1000nwz?src=rss
Author :
Publish date : 2026-07-15 12:39:00
Copyright for syndicated content belongs to the linked Source.